Results 311 to 320 of about 433,927 (377)

Neutrophils as key drivers of pulmonary fibrosis: unveiling mechanisms and therapeutic implications. [PDF]

Front Immunol
Liang X, Li Y, Tang Z, Luo Y, Liu Y.
europepmc   +1 more source

Integrating "Yang transforming Qi and Yin constituting the body" with immune regulation: an evidence synthesis of multidimensional traditional chinese medicine therapy for immune thrombocytopenia. [PDF]

Chin Med
Zhou X, Jiang Y, Hou M, Shan N.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Receptors | Platelet-Activating Factor Receptor

Encyclopedia of Biological Chemistry III, 2021
Katherine M. Howard, Justin J. Miller
openaire   +2 more sources

Antiobese function of platelet‐activating factor: increased adiposity in platelet‐activating factor receptor‐deficient mice with age

The FASEB Journal, 2013
Platelet‐activating factor receptor (PAFR)‐deficient mice developed a more severe obese state characterized by higher body mass (~25%) and epididymal fat mass (~55%) with age than that of wild‐type (WT) littermates. PAFR‐deficient mice did not show changes in the expression of critical genes involved in anabolic and catabolic ...
Junko, Sugatani, Satoshi, Sadamitsu, Masahiko, Yamaguchi, Yasuhiro, Yamazaki, Ryoko, Higa, Yoshiki, Hattori, Takahiro, Uchida, Akira, Ikari, Wataru, Sugiyama, Tatsuo, Watanabe, Satoshi, Ishii, Masao, Miwa, Takao, Shimizu   +12 more
openaire   +3 more sources

Platelet activating factor receptor

Trends in Pharmacological Sciences, 1996
The human platelet-activating factor receptor gene exists as a single copy on chromosome 1. Two 5'-noncoding exons (Exon 1 and 2) has distinct transcription initiation sites and promoters. These exons are alternatively spliced to a common splice acceptor site on exon 3 that contains a total coding regions.
T, Shimizu, H, Mutoh, S, Kato
  +5 more sources

Platelet-activating factor receptor

Prostaglandins & Other Lipid Mediators, 2002
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid mediator. Although PAF was named for its potential to induce platelet aggregation, intense investigations have elucidated potent biological actions of PAF in a broad range of cell types and tissues.
Zen-ichiro, Honda, Satoshi, Ishii, Takao, Shimizu   +2 more
openaire   +3 more sources

Platelet Activating Factor Receptors

2003
Platelet activating factor (PAF) is a potent pro-inflammatory lipid mediator. Its effects are mediated through cell surface G protein-coupled receptors (GPCRs) that are distributed on numerous cells notably on endothelium [1]. An intracrine mode of action for PAF is proposed based on evidence for intracellular PAF binding sites [2] and retention of ...
A Marilise, Marrache, Fernand, Gobeil, Sylvie G, Bernier, Jana, Stankova, Marek, Rola-Pleszczynski, Sanaa, Choufani, Ghassan, Bkaily, Annie, Bourdeau, Martin G, Sirois, Alejandro, Vazquez-Tello, L, Fan, Jean-Sebastien, Joyal, Janos G, Filep, Daya R, Varma, Alfredo, Ribeiro-Da-silva, Sylvain, Chemtob   +15 more
openaire   +2 more sources

Binding of carbamyl-platelet-activating factor to the raji lymphoblast platelet-activating factor receptor

International Journal of Immunopharmacology, 1992
Carbamyl-platelet-activating factor (1-hexadecyl-2-N-methylcarbamyl-glycero-3-phosphocholine; CPAF) is an analog of platelet-activating factor (PAF) containing an N-methylcarbamyl moiety at the sn-2 position. CPAF was tested for effects on the Raji lymphoblast PAF receptor.
J B, Travers, Q, Li, H, Sprecher, R H, Fertel   +3 more
openaire   +2 more sources